CD8-Positive Lymphocytes in Graft-Versus-Host Disease of Humanized NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ Mice

    February 2015 in “ Journal of comparative pathology
    Steven T Laing, Stephen M. Griffey, Mary E. Moreno, Cheryl A. Stoddart
    Image of study
    TLDR CD8+ T cells play a key role in graft-versus-host disease in certain mice models.
    The study investigated NSG-hu-BLT mice, which are immunocompromised mice engrafted with human fetal liver and thymus, to model human immune system functions. Four mice developed alopecia, pruritus, and lethargy after HSPC engraftment, and histopathology revealed signs of graft-versus-host disease (GvHD), including keratinocyte and hepatocyte cell death associated with CD8+ T lymphocytes. This highlighted the role of CD8+ T cells in GvHD progression and suggested that while NSG-hu-BLT mice are valuable for studying GvHD, their susceptibility to the disease might limit their utility in other biomedical research areas.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results

    Related Community Posts Join

    6 / 1000+ results
      If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied

      community If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied

      in Research  828 upvotes 5 months ago
      Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.
      [object Object]

      community Kintor Phase 2 Results released KX-826 (pyrilutamide)

      in Research/Science  450 upvotes 2 years ago
      Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

      community Alopecia Areata Question

      in Treatment  2 upvotes 3 years ago
      A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.

    Similar Research

    5 / 1000+ results